Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class ...

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co (“Merck” or th ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

The health secretary is planning to remove members of a panel that recommends vaccines if he sees conflicts of interest.

Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. Read more to see 2 ...

February 20, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...

Three mega-cap names recently announced billions in share repurchase authorizations. Mega-cap generally refers to stock with market capitalizations of $200 billion or more. Below, I’ll detail exactly ...

Merck & Co.'s first trial over the safety of its blockbuster cancer vaccine Gardasil was postponed mid-trial due to concerns that jurors might be influenced by media coverage surrounding the ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...